The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: A trial-based analysis

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Pho, Mai T ^a   Swaminathan, Soumya ^b   Kumarasamy, Nagalingeswaran ^c   Losina, Elena ^d,e,f   Ponnuraja, C ^b   Uhler, Lauren M ^d   Scott, Callie A ^d   Mayer, Kenneth H ^h   Freedberg, Kenneth A ^d,f,g   Walensky, Rochelle P ^d,e  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c VHS Medical Centre India   (India)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; INFECTION PREVENTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PATIENT COMPLIANCE; SIDE EFFECT; TOXIC HEPATITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COST-BENEFIT ANALYSIS; ETHAMBUTOL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; ISONIAZID; MALE; MODELS, ECONOMIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84860444364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036001     Document Type: Article

References (57)

1. Steinbrook R, (2007) Tuberculosis and HIV in India. N Engl J Med 356: 1198-1199.
2. Swaminathan S, Nagendran G, (2008) HIV and tuberculosis in India. J Biosci 33: 527-537.
3. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, et al. (2000) Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 4: 839-844.
4. WHO, (2008) Global tuberculosis control: surveillance, planning, financing Geneva: World Health Organization.
5. Swaminathan S, Subbaraman R, Venkatesan P, Subramanyam S, Kumar SR, et al. (2008) Tuberculin skin test results in HIV-infected patients in India: implications for latent tuberculosis treatment. Int J Tuberc Lung Dis 12: 168-173.
6. WHO, (2009) Three I's meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva World Health Organization.
7. TB India, (2011) RNTCP Status Report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. New Delhi.
8. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21 (Suppl 4): S117-128.
9. Swaminathan S, Menon PA, Venkatesan P, Kumar S, Ramachandran R, et al. (2010) Efficacy of a 6-month vs. a 36-month regimen for the prevention of TB in HIV-infected persons in India A randomized clinical trial. [abstract 103]. 17th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, USA.
10. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, et al. (2010) Cost-Effectiveness of HIV Testing Referral Strategies among Tuberculosis Patients in India. PLoS One 5: e12747 doi:12710.11371/journal.pone.0012747.
11. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD, (2007) Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis 45 (Suppl 4): S248-254.
12. Gold RM, Seigel EJ, Russell BL, (1996) Cost-effectiveness in health and medicine. New York Oxford University Press.
13. World Economic Outlook Database (2009) International Monetary Fund.
14. WHO, (2001) Macroeconomics and health: Investing in health for economic development. Report for the Commission on Macroeconomics and Health. Geneva World Health Organization.
15. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831.
16. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
17. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, et al. (2010) Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 10: 489-498.
18. NACO, (2007) Guidelines for prevention and management of common opportunistic infections/malignancies among HIV-infected adult and adolescent. Ministry of Health and Family Welfare. Government of India.
19. Bachani D, Rewari BB, (2009) Antiretroviral therapy: practice guidelines and National ART Programme. J Indian Med Assoc 107 308, 310-304, 316 passim.
20. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H,et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365: 11-20.
21. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (1588-1598).
22. WHO, (2011) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland.
23. Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, et al. (2005) Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India. Int J Tuberc Lung Dis 9: 896-900.
24. Kumarasamy N, Solomon S, Chaguturu SK, Cecelia AJ, Vallabhaneni S, et al. (2005) The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 41: 1525-1528.
25. Wang B, Kumarasamy N, Divi N, Cecelia A, Mayer K, et al. (2006) Incidence of opportunistic infections (OIs) within specific CD4 strata in HIV-infected patients in southern India. [abstract WePe0279]. 16th International AIDS Conference. Toronto, Canada.
26. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, et al. (2007) The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther 12: 543-551.
27. Minga A, Danel C, Abo Y, Dohoun L, Bonard D, et al. (2007) Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ 85: 116-123.
28. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, et al. (2007) Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses 23: 1338-1347.
29. Badri M, Wilson D, Wood R, (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359: 2059-2064.
30. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283: 2537-2545.
31. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52-59.
32. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
33. Unit costs for components of HIV-related health care (2009) YRG Pharmacy. Chennai, India.
34. Monthly Index of Medical Specialties, (2010) 30.
35. Muniyandi M, Rajeswari R, Balasubramanian R, (2006) Estimating provider cost for treating patients with tuberculosis under Revised National Tuberculosis Control Programme (RNTCP). Indian Journal of Tuberculosis 53: 12-17.
36. NACO, (2010) Care, Support & Treatment: National AIDS Control Programme, Phase-III, India. Ministry of Health & Family Welfare.
37. Homan RK GA, Duraisamy P, Castle C, Sripriya M, Franklin B, Solomon S, (2000) Economic Analysis of YRG CARE Services,. Research Triangle Park Family Health International.
38. Akolo C, Adetifa I, Shepperd S, Volmink J, (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev.
39. WHO, (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Geneva World Health Organization.
40. Hausler HP, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, et al. (2006) Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 84: 528-536.
41. John KR, Daley P, Kincler N, Oxlade O, Menzies D, (2009) Costs incurred by patients with pulmonary tuberculosis in rural India. Int J Tuberc Lung Dis 13: 1281-1287.
42. Shrestha RK, Mugisha B, Bunnell R, Mermin J, Odeke R, et al. (2007) Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis 11: 747-754.
43. Sutton BS, Arias MS, Chheng P, Eang MT, Kimerling ME, (2009) The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia. Int J Tuberc Lung Dis 13: 713-718.
44. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365: 2155-2166.
45. Menzies D, Al Jahdali H, Al Otaibi B, (2011) Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 133: 257-266.
46. Menzies D, Long R, Trajman A, Dion MJ, Yang J, et al. (2008) Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149: 689-697.
47. Bell JC, Rose DN, Sacks HS, (1999) Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 13: 1549-1556.
48. Masobe P, Lee T, Price M, (1995) Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients-a least-cost analysis. S Afr Med J 85: 75-81.
49. Howard AA, El-Sadr WM, (2010) Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis 50 (Suppl 3): S238-244.
50. Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, et al. (2010) Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med 182: 278-285.
51. Hovell M, Blumberg E, Gil-Trejo L, Vera A, Kelley N, et al. (2003) Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis. Soc Sci Med 56: 1789-1796.
52. Machado A Jr, Finkmoore B, Emodi K, Takenami I, Barbosa T, et al. (2009) Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis 13: 719-725.
53. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, et al. (2009) Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 23: 631-636.
54. WHO, (2010) Multidrug and extensively drug-resistant TB: Global report on surveillance and response. Geneva World Health Organization.
55. Cecelia AJ, Christybai P, Anand S, Jayakumar K, Gurunathan T, et al. (2006) Usefulness of an observational database to assess antiretroviral treatment trends in India. Natl Med J India 19: 14-17.
56. Pardeshi G, (2009) Survival analysis and risk factors for death in tuberculosis patients on directly observed treatment-short course. Indian J Med Sci 63: 180-186.
57. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, et al. (2009) Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29: 503-510.